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OBJECTIVES: Over two-thirds of the US population are overweight or obese. While
current pharmacotherapy options for weight loss are limited, new weight loss
products have not been approved partly over safety concerns, including some
linked to weight-related illnesses such as hypertension. However, very little is
known about the association of available weight-loss pharmacotherapy with
changes in drug therapy for weight-related illnesses. METHODS: A retrospective
cohort analysis of a deidentified pharmacy claims database evaluated adult pa-
tients initiating weight-loss pharmacotherapy (no weight-loss drug prescriptions 6
months prior) between November 1, 2007 – October 31, 2010. Patients with contin-
uous eligibility for 6 months pre- (baseline) and 6 months post- weight-loss drug
initiation were evaluated for changes in concomitant drug therapy associated with
weight-related illnesses (hypertension, dyslipidemia, type 2 diabetes, anxiety, gas-
trointestinal disorders, depression, and hypothyroidism). Six-month outcomes in-
cluded concomitant therapy incidence, and net change (% patients adding1 drug
minus % discontinuing 1 drug in each illness category) analyzed using t-test
(significance at p0.05). RESULTS: A total of 91,160 patients initiated weight-loss
pharmacotherapy: phentermine (N67,434), sibutramine (N13,438), orlistat
(N8,047), phendimetrazine (N4,631), and diethylpropion (N 4,350); meanSD
age 4412 years (96%, 18-64 y/o), 82% female. Patients received 1.50.8 concomi-
tant weight-related illness drugs at baseline for hypertension (21.6%) depression
(14.9%), dyslipidemia (11.5%), hypothyroidism (9.2%), gastrointestinal disorders
(9.6%), anxiety (6.7%), and diabetes (5.5%). Incident/net therapy change over 6
months for each illness category: hypertension (3.2%/-6.5%), depression (0/-16.0%),
dyslipidemia (1.1%/-12.2%), hypothyroidism (1.2%/0.7%), gastrointestinal disor-
ders (0.2%/-17.1%), anxiety (1.1%/-19.4%), and diabetes (0.6%/-8.9%). All net changes
from baseline are significant (p0.05), with the exception of hypothyroidism
therapy. CONCLUSIONS: Concomitant therapy for obesity-related illnesses gener-
ally has a low incidence and declines significantly over 6 months after initiating
weight-loss pharmacotherapy. Antihypertensive and hypothyroidism therapy ap-
pear to follow different patterns, and whether this reflects disease progression,
effect of weight-loss therapy, genetics, or other factors warrants further investiga-
tion.
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OBJECTIVES: Haemophilia is one of the rare diseases in Iran; the government le-
gally has to cover its costs completely. Total drug subsidies are 320 millions USD
and 30% of subsidies have been allocated for the blood coagulating factors. There
are 3900 and 1100 registered patients with haemophilia A and B respectively which
190 of them are haemophilia with inhibitors. 17% of total drug subsidies have been
allocated for two bypassing agents; recombinant Factor VIIa and activated pro-
thrombin complex concentrate. The ministry of health has proposed a new guide-
line for managing costs of haemophilia with inhibitors so this study tries to esti-
mate cost of bypassing agents in this protocol and compares it with the current
situation. METHODS: For estimating the costs of new protocol, the price of medi-
cines and the patients’ information and statistics were taken from the Ministry of
Health and National Haemophilia Foundation. Information about responding to
different treatments and effectiveness of these two medicines were extracted from
evidence based literatures and systematic reviews. RESULTS: Based on new proto-
col the average cost for each bleeding episode is 1960 USD; it means 9 million USD
for 190 patients annually. A sensitivity analysis shows it can vary from 4 to 14
million USD. The current expenditure for these two bypassing agent is more than
45 million USD annually.CONCLUSIONS: The study shows the cost of new protocol
for 190 patients with inhibitors is 9 million USD annually; it could be 14 million USD
in the worst situation. This is 25 percent of current cost that has been paid for these
two bypassing agents. This notable gap may occur because of some reasons such as
smuggling to neighbors, off label uses, irrational drug use, inefficient patient man-
agement and moral hazards. The absence of efficient guideline not only causes
wasting limited resources but also increases risky behaviors.
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OBJECTIVES: Peripheral blood stem cell transplantations (PBSCT) are very expen-
sive life-saving medical procedures carried out in patients with haematological
disease. The current tariffs are expected to be too low due to developments in
treatment protocols. A revision of the tariffs is urgently necessary. We calculated
the cost of PBSCT for treating haematological diseases in Dutch daily practice, to
provide a proper basis for revising hospital budgets. METHODS: From three Dutch
university hospitals, we randomly selected 191 patients who underwent an autol-
ogous (auto) or allogeneic (allo) PBSCT in 2008 or 2009. The alloPBSCT were subcat-
egorised into sibling, matched unrelated donor (MUD) and unrelated cord blood
(UCB). We obtained data from hospital registrations to study all treatment related
activities. Unit prices were based both on real costs and tariffs (base year 2010).
Thereafter, the average costs per patient per PBSCT and per period were calculated.
The total cost included the selection and harvesting, transplantation and 1-year
follow-up. RESULTS: The average cost per patient of autoPBSCT were € 45,670. The
cost of sibling alloPBSCT were € 101,919. The average cost of transplantations from
an unrelated donor were much higher: € 171,478 for MUD and € 254,689 for UCB
alloPBSCT. Hospital days, laboratory procedures and donor search were the largest
cost components and mainly responsible for differences between the four types of
PBSCT. None of the patient characteristics were correlated with average cost. The
costs calculated in this study are above current reimbursement. The difference is
significant (p0.043) and depending on the type of PBSCT, the shortfall varied
between 2% and 100%. CONCLUSIONS: Average cost of AutoSCT and alloSCT laid
above current reimbursement levels. Appropriate financing is necessary to guar-
antee the continuation of PBSCT in Dutch patients according to current indications.
The costs calculated in this study provide reliable input for economic evaluations.
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OBJECTIVES: Obesity has reached epidemic proportions and has many cost impli-
cations, including increases in medical spending and productivity losses in the
workplace. Many studies have found a correlation between workers obesity and
absenteeism (days missed from work) and presenteeism (losses in on the job pro-
ductivity). Our study examines the impact of a worksite weight management pro-
gram on workforce productivity. METHODS: The Work Limitations Questionnaire
(WLQ) was administered to study participants (N379) at beginning and end of 2-
year trial. Employees were asked about their productivity during the previous 2
weeks of work and to rate any impairment they had in the areas of time, physical,
mental-interpersonal and output demands on a five-point scale. The resulting
WLQ productivity loss score was converted to a percent of time lost. Using a t-test,
we compared mean productivity and BMI changes over 2 years between the study
groups. RESULTS: The intervention arm had a mean BMI of 27.85 and 27.93 at
baseline and follow-up, respectively, vs. 28.22 and 28.46 in the control arm. The
average percent lost productivity for the intervention group was no different from
that in the control group (2.20% vs. 2.37%, p0.05). At the two year follow-up, the
intervention group saw an increase in lost productivity at 2.44% and the control
group saw a decrease at 2.11%. CONCLUSIONS: Our results suggest that having a
weight management program does not necessarily improve productivity of the
workforce. Future studies should further examine the relationship between obe-
sity, weight loss and productivity as well as methods to increase productivity of the
working population.
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OBJECTIVES: Waist circumference (WC) is considered an indicator of cardiovascu-
lar and metabolic risk therefore it is important to assess electronic WC recording in
general practice. This study evaluated the level of WC recording in UK primary care
and its association with body mass index (BMI). METHODS: WC recording in The
Health Improvement Network (THIN) between 2007 and 2010 was assessed. Pa-
tients with and without WC records were counted by practice, year and BMI cate-
gory (underweight 18.5kg/m2, normal 18.5-25kg/m2, overweight 25-30kg/
m2, obese30kg/m2, no BMI record). Patients were registered at the practice for the
entire year. Only WC and BMI records during the year of interest were included.
RESULTS: From 2007-2010 there were 59,193 patients (1.4%) with a WC record. WC
recording increased over time from 0.9% of patients in 2007 to 1.6% in 2010. How-
ever, there were still 69 practices (15.7%) with no WC records during 2010. Overall,
patients with a WC record had a mean age of 60.9 years (standard deviation (SD):
17.4), mean WC of 90.4cm (SD:15.0) and 53.2% were male. Patients without a WC
record had a mean age of 49.5 years (SD:21.5) and 49.5% were male. 2.1% and 78.2%
of patients with and without a WC record respectively did not have a BMI record. Of
patients with BMI and WC, 0.7% were underweight, 20.9% normal, 36.4% over-
weight and 42.0% obese, whereas patients without WC were categorised as 2.8%,
32.7%, 33.2% and 31.3% respectively. CONCLUSIONS: Despite the WC recording
percentage being low, nearly sixty thousand patients had a WC record and record-
ing increased over time. Research would therefore benefit from investigating later
years. GPs seemed more likely to record WC for patients with high BMI, therefore
research using WC should investigate any potential bias this may introduce. Future
studies could investigate associations between WC recording and other factors.
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OBJECTIVES: The Treatment Satisfaction with Medicines (SATMED-Q) question-
naire has shown appropriate psychometric properties exploring patient=s satisfac-
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